Clinical trials in T-cell lymphoma

The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for T-Cell lymphoma patients.

To find out how you can access one of these clinical trials or to contact us with a question, see our page 'How to be referred'. 

For an explanation on the different phases of trials click here.

 

 

Trial Name

 

Description

 

Click the link for more information (external page)

 

AB10004

 

Phase 2-3 study looking at the inhibitor masitinib alone and with chemotherapy

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

Arroven

 

Study looking at the safety of Brentuximab Vedotin, a CD30-targeting antibody-drug conjugate.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

C25006

 

Phase 4 study of Brentuximab vedotin, a CD30-targeting antibody-drug conjugate

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

CITADEL

 

Phase 2 study investigating the efficacy of autologous EBV-specific T-cells.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

RESMAIN

 

Phase 2 study testing resminostat as treatment for people with mycosis fungoides (MF) or Sézary syndrome (SS), a type of cutaneous (skin) T-cell lymphoma.

Suitable for patients who have received treatment and their lymphoma is stable or in remission

 

 

 

ROMI-CAR

 

Phase 1-2 study looking at the dosage and effectiveness of new drugs romidepsin and carfilzomib

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

PROCLIPI

 

A non-medicinal (observational) clinical trial involving collecting data on patients with mycosis fungoides (primary cutaneous T cell lymphoma) and Sézary syndrome (SS), to help determine how we manage future patients.

 

 

 

*Please note, we update this page fortnightly

With special thanks to the following:

;